Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by stockarchangelon Apr 11, 2014 5:03pm

215 Views

Post# 22442051

RE:Dilution

LOL.....think small and suspect the worst. It's part of the Vancouver mentality. Top 5 biotechs and their share data:
Amgen - 771 million shares at $78
Gilead - 757 million shares at $53
Biogen - 236 million shares at $145
Teva - 868 million shares at $39
Baxter - 547 million shares at $59

SBM has under 200 million (fully diluted) at this stage, but will probably need a bit more financing to get to revenue independence. Also anticipating RS to qualify for NASDAQ. Certainly NOT diluted to oblivion.

Bullboard Posts

Options trading in a volatile macro environment